- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.24 | Tharimmune files to sell 1.44 million shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
| 16.12.24 | Tharimmune plans Phase 2 trial for itch treatment TH104 | 3 | Investing.com | ||
| 16.12.24 | Tharimmune, Inc.: Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update | 195 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology... ► Artikel lesen | |
| 06.12.24 | Tharimmune announces $2.02M private placement; shares up | 1 | Seeking Alpha | ||
| 06.12.24 | Tharimmune secures $2.02 million in private funding | 2 | Investing.com | ||
| 06.12.24 | Tharimmune, Inc.: Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs | 331 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology... ► Artikel lesen | |
| 06.12.24 | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| THARIMMUNE Aktie jetzt für 0€ handeln | |||||
| 21.11.24 | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.11.24 | Tharimmune Inc.: Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting to Support TH104 for Chronic Pruritus in Chronic Liver Disease | 179 | ACCESS Newswire | Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary... ► Artikel lesen | |
| 13.11.24 | Tharimmune COO Appajosyula Sireesh erwirbt Aktien im Wert von 10.096 US-Dollar | 2 | Investing.com Deutsch | ||
| 13.11.24 | Tharimmune erhält europäisches Patent für Krebstherapie-Technologie | 2 | Investing.com Deutsch | ||
| 13.11.24 | Tharimmune set to receive European patent for cancer therapy tech | 2 | Investing.com | ||
| 13.11.24 | Tharimmune Inc.: Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics | 239 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 07.11.24 | Tharimmune, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.24 | Tharimmune Inc.: Tharimmune Announces Upcoming Conference Presentations | 204 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 30.10.24 | What's Going On With Tharimmune Shares Wednesday? | 2 | Benzinga.com | ||
| 30.10.24 | Tharimmune secures EMA feedback on pruritus drug trial | 3 | Investing.com | ||
| 30.10.24 | Tharimmune erhält positives Feedback der EMA für Pruritus-Medikamententest | 9 | Investing.com Deutsch | ||
| 30.10.24 | Tharimmune Inc.: Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis | 225 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 28.10.24 | Tharimmune Inc.: Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting | 337 | ACCESS Newswire | TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profileTH104 was well tolerated with no unexpected... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 54,04 | +7,05 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| QIAGEN | 44,560 | -3,20 % | DAX-Check LIVE: Munich Re, Qiagen, Rheinmetall, Siemens Energy, SUSS, Zalando im Fokus | Bereits kurz nach Handelsstart markierte der DAX gestern mal wieder ein neues Allzeithoch. Und dieses hatte dann auch bis zum Ende des Tages bestand. Es liegt bei 20.675 Punkten. 20 Zähler darunter... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 14,120 | +396,31 % | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 | ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid... ► Artikel lesen | |
| DISC MEDICINE | 57,44 | -1,95 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| BIONTECH | 117,00 | +5,69 % | Evotec, Vidac Pharma, BioNTech - Geld verdienen mit dem Kampf gegen Krebs | Nicht erst seitdem König Charles und Prinzessin Kate ihre Krebsleiden öffentlich gemacht haben ist klar, dass die Krankheit jeden treffen kann. Der Markt wächst und schon heute gehen die Umsätze in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,670 | +2,40 % | Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday | ||
| EVOTEC | 7,910 | -1,12 % | Evotec-Aktie leicht im Minus (7,725 €) | Am deutschen Aktienmarkt notiert die Aktie von Evotec zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 7,73 Euro. Für Inhaber von Evotec ist der heutige Handelstag bisher nicht... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 7,220 | +107,47 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| VERVE THERAPEUTICS | 8,320 | +6,67 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
| MODERNA | 37,315 | +0,21 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| JANUX THERAPEUTICS | 45,080 | +12,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ARCELLX | 65,54 | -1,55 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,830 | +5,66 % | Why Summit Therapeutics Stock Is Jumping Today | ||
| SPRINGWORKS THERAPEUTICS | 36,220 | +3,41 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| ABSCI | 4,185 | +3,98 % | Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside |
Das Unternehmen THARIMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THARIMMUNE INC finden Sie auf Wallstreet Online.
